DWW Investment

Doctor of Theoretical Journalism, graduated from the School of Journalism of Fudan University, China Europe International Business School and Harvard Business School; Published best-selling books "Deciphering Shanghai 1990 - 2000" and "Witness to China Finance"; formerly the editor-in-chief of the East China Branch of the People’s Daily, the president of the International Finance News, and the vice president of Shanghai Culture, Radio, Film and Television Group; Lead the pre-content planning of the theme pavilion, China pavilion, future pavilion, and Shanghai pavilion of the 2010 Shanghai World Expo; Executive Vice Chairman and Secretary General of the 9th and 10th Shanghai International Film and Television Festival.

Ph.D., EMBA from Tsinghua Wudaokou School of Finance and China Europe International Business School. Served as a cadre of People's Daily, Vice Chairman of People's Video, CSO of China City Network Television Co., Ltd., Senior Vice President of Visual China Group (000681SH), Chairman of Peking University Culture, and General Manager of Shanghai Youth Media. Participated in the management of a number of private equity investment funds. Participated in the management of several private equity investment funds. He has published many books and with extensive experience in the TMT field he has led and participated in many successful investment and M&A projects in the TMT field.

Dual bachelor's degree in materials science and engineering and industrial management engineering from Shanghai Jiaotong University, a master's degree in management science from Antai School of Management. He has served as senior manager of investment banking department of Junan Securities and China Merchants Securities, executive of domestic listed companies, founding partner of Shanghai Lingqing Venture Capital Management Co., Ltd., his investment protfolio including Longyun (603729), Shanghai Qiangjing (injected 002542), Mobvista Technology (HK1860), Haiyou New Materials (688680), Baichuan Changyin (300614), Zhenlei Technology (GEM review has been approved) and other projects, with 20 years of capital market related experience, equity investment, corporate restructuring and listing, market value management of listed companies and M&A. He has a unique vision and profound insights into industry development with emphasis on risk control, and focus on investments that are forward-looking and innovative.

Bachelor of Mechanical Engineering from Southwest Petroleum University, Master of Building Engineering from Concordia University (Canada), Master of Real Estate Development from MIT Massachusetts Institute of Technology (USA). In 2007, began to engage in real estate private equity investment and financing in M3 Capital Co., Ltd. in the United States.

Bachelor of Mechanical Engineering, Tsinghua University, MBA from the City University of America. Mr Chu has 25 years of experience in commercial bank management and credit, served as president of the Nanjing Branch of Bank of East Asia and Vice President of Capital Bank China LTD. In 2020, Chu joined Watermark China, responsible for the company's investment, financing, and strategy implementation, and served as the general manager of Jiangsu Watermark Company. He also served as vice president at the Association of Foreign Invested Enterprises, Beijing Investment Promotion Bureau; vice-chairman of Foreign Investment Committee, China Investment Association, NDRC and is invited as a member of the 13th Session of Nanjing CPPCC.

Bachelor of Mechanical Engineering, Tsinghua University, MBA from the City University of America. Mr Chu has 25 years of experience in commercial bank management and credit, served as president of the Nanjing Branch of Bank of East Asia and Vice President of Capital Bank China LTD. In 2020, Chu joined Watermark China, responsible for the company's investment, financing, and strategy implementation, and served as the general manager of Jiangsu Watermark Company. He also served as vice president at the Association of Foreign Invested Enterprises, Beijing Investment Promotion Bureau; vice-chairman of Foreign Investment Committee, China Investment Association, NDRC and is invited as a member of the 13th Session of Nanjing CPPCC.

Chad Oh, MD, DWW Chief Medical Advisor, has more than 30 years of therapeutic clinical development experience in both industry and academia with a focus on CNS, infectious, respiratory, and autoimmune diseases, cancer and related rare diseases. He effectively facilitated the development of small molecules and biologics for therapeutic indications and led multiple submissions to U.S., European and Asian regulatory authorities to register these products for marketing, this including over 30 IND submissions, 20 505(b)(2) submissions, completed three NDAs, and completed one BLA. Dr. Oh is the CMO at AEON. Prior to that, Dr. Oh held senior leadership roles in Clinical Development at Revance, Glenmark Pharmaceuticals and Medimmune/AstraZeneca and the Weinberg Group. Before joining the private sector, he spent 13 years at UCLA School of Medicine where he served as Associate Professor of Pediatrics and Head of the Allergy/Immunology and Rheumatology Clinics at Harbor-UCLA Medical Center. He has authored over 70 peer-reviewed publications and holds several patents. Dr. Oh received his M.D. from the Kyung-Hee University School of Medicine, Seoul, South Korea.

Mr. Liu is currently the Scientific Advisor of DWW investment, and Chief Operation Officer and Board Member in Fulgent Life LLC, overseeing the development of multiple biopharma products. He was previously head of Biostatistics of a publicly traded biotechnology company and assisted in managing multiple projects in collaboration with company’s business partners in the US and in China. He was the site head of a biostatistics team supporting the CMC, non-clinical, preclinical and medical affairs in Allergan. He graduated from Queen’s University in Canada and held a Master of Science degree in Statistics (Specialize in Bioscience), Bachelor of Science degrees in Statistics (Specialize in Actuarial Science) and a Bachelor of Art degree in Economics. He also studied analytical chemistry for a few years.

Mr. Liu has been involved in research and development in Innovative drugs, generics, and biosimilar products. and participated in more than 300 drug marketing applications for FDA, TPP, and EMEA in ANDA, IND, NDA, and BLA. He has more than 20 years of experience in pharmaceutical research and development and coauthor multiple medical research papers. He established multiple automated data analysis systems, which greatly reduced the data processing errors and the calculation errors, and shortened the preparation time for the application document. He had worked with or supported the following companies: Revance, Fosun Pharma, TEVA, Allergan, Novartis, Sandoz, Mylan, Apotox, Valeant, Amgen, Dr. Reddy’s Laboratory, Par Pharmaceuticals, Actavis, Watson, etc.